Evolus (EOLS) Net Income towards Common Stockholders (QoQ) (2017 - 2026)
Evolus (EOLS) Net Income towards Common Stockholders (QoQ) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - |
| 10 | Evolus | 550.51 Mn | 505.34 Mn | 57.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 24.56% |
| Mar 31, 2026 | -8,310.77% |
| Dec 31, 2025 | 100.83% |
| Sep 30, 2025 | 8.20% |
| Jun 30, 2025 | 9.26% |
| Mar 31, 2025 | -178.19% |
| Dec 31, 2024 | 64.57% |
| Sep 30, 2024 | -68.90% |
| Jun 30, 2024 | 13.42% |
| Mar 31, 2024 | -10.80% |
| Dec 31, 2023 | 30.09% |
| Sep 30, 2023 | 6.71% |
| Jun 30, 2023 | -22.64% |
| Mar 31, 2023 | -12.36% |
| Dec 31, 2022 | 35.08% |
| Sep 30, 2022 | 13.61% |
| Jun 30, 2022 | -34.11% |
| Mar 31, 2022 | 3.72% |
| Dec 31, 2021 | 6.46% |
| Sep 30, 2021 | -24.56% |